Delivery Order 36F79719D0153-36C26223F0045
Award Date
10/27/22
Potential Completion Date
10/26/23
Potential Value
$246K
Federal Agency
Veterans Integrated Service Network 22
Awardee
Genzyme Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Genzyme Corporation, doing business as Sanofi Genzyme, a global healthcare and pharmaceutical company. The contract is for the delivery of the specialty pharmaceutical Cerdelga (eliglustat) to support treatment programs for veterans. The contract was awarded under Genzyme's existing $659 million multiple award Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs with the VA, as...
This is a federal contract award to Genzyme Corporation, doing business as Sanofi Genzyme, by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The award has a ceiling value of $161,979.21 and is a delivery order under Genzyme's existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract valued at $659 million. The delivery order is for the specialty pharmaceutical product Cerdelga (eliglustat), which is used to treat Gaucher's disease. The...
The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order contract to Genzyme Corporation, a division of Sanofi Genzyme, to provide the drug CERDELGA. The contract has a potential value of $106,912.80 and a completion date of March 31, 2019. Genzyme is the prime contractor on this award, which was placed against the company's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a multiple award schedule managed by the VA. The...
This delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule, awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22, is for an emergency pharmaceutical order of 84mg Eliglustat Cerdelga tablets from Genzyme Corporation. The $20,049.02 firm fixed price order issued to Genzyme Therapeutics Division, a division of Sanofi Genzyme, will supply the needed medication to the Veterans Integrated Service Network 22 by...
This is a federal contract award for the delivery of the pharmaceutical product CERDELGA to the Department of Veterans Affairs (VA) Veterans Health Administration. The contract was awarded to the prime contractor Genzyme Corporation, a division of Sanofi Genzyme, on a firm fixed price basis. The contract has a potential value of $106,943.55 and was issued as a delivery order against Genzyme's existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the VA. The...
This is a federal contract award to Genzyme Corporation, doing business as Sanofi Genzyme, for pathology testing services. The $99,200.15 firm-fixed-price delivery order was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration under Genzyme's $659 million Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. This master contract allows the VA to issue task orders for a broad range of drug and pharmaceutical products over a 5-year period. Genzyme...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 awarded a $124,840.80 delivery order to Genzyme Corporation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) for eliglustat/Cerdelga capsules. As the prime contractor, Genzyme Therapeutics Division will deliver the requested pharmaceutical products to a place of performance in Riverwoods, Illinois. No set-aside designation was used for this contract awarded to support...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 awarded a $265,045.04 firm fixed price delivery order to Genzyme Corporation, doing business under its Genzyme Therapeutics Division, for eliglustat medication. The period of performance is from October 1, 2020 to September 30, 2021. The delivery order was awarded against Genzyme Corporation's Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $212,340.40 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule contract to Genzyme Corporation for the bulk purchase of 84mg oral capsules of Eliqlustat (Cerdelga). Performance will take place in Cambridge, Massachusetts with no set-aside designation applied. Genzyme Therapeutics Division, doing business as Sanofi Genzyme, will serve as the...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 12 (VISN 12) to Genzyme Corporation, doing business as Sanofi Genzyme, for the pharmaceutical product Alemtuzumab 12mg/1.2ml Injection Vial (Lemtrada). The order is for $75,125.05 and was issued under Genzyme's Federal Supply Schedule (FSS-61-IB) Pharmaceuticals and Drugs contract with the VA. This delivery order has no set-aside designation. Genzyme Corporation is the...